Intrinsiqq
Hemogenyx Pharmaceuticals Plc logo

Hemogenyx Pharmaceuticals Plc Financials

HEMO.XLON

Compare

All currency values in £ millions unless otherwise noted

Scroll

Income Statement
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue£0£0£0£0£0
Cost of Revenue£1–––£0
Gross Profit-£1–––-£0
General & Administrative–£5£6£3–
Total Operating Expenses£4–––£3
Operating Income-£5£5£6-£4-£3
Non-Operating
Net Interest Expense-£0-£0-£0-£0-£3
Other Non-Operating Income (Expense)–-£11-£13£0–
EBT (Earnings Before Tax)–-£6-£7-£4–
Income Tax Expense£0£0£0£0£0
Earnings from Continuing Ops–-£6-£7-£4–
Minority Interest–-£0-£0-£0–
Net Income
Net Income-£10-£6-£7-£4-£5
Per Share Data
Revenue Per Share£0.00£0.00£0.00£0.00£0.00
EPS (Basic)-£1.71-£1.81-£2.37-£2.00-£0.01
EPS (Diluted)-£1.71-£1.81-£2.37-£2.00-£0.01
Shares Outstanding5.7M3.1M2.8M2.0M729.8M

Hemogenyx Pharmaceuticals (HEMO.XLON) financials: revenue, profit and margins

Hemogenyx Pharmaceuticals (HEMO.XLON) generated about £0.00 in revenue and -£10 million in net income over the trailing twelve months. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is Hemogenyx Pharmaceuticals's (HEMO.XLON) revenue?+

Hemogenyx Pharmaceuticals generated about £0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Hemogenyx Pharmaceuticals profitable?+

Hemogenyx Pharmaceuticals reported about -£10 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

Peers

Biotechnology · Pick stocks to compare with HEMO.XLON

CompareIntrinsic value
EVG.XLONEvgen Pharma PLC
£0.00-2.42%40
AZN.XLONAstraZeneca PLC
£134.12+0.81%56
SPI.XLONSpire Healthcare Group plc
£2.49+0.61%63
ROQ.XLONRoquefort Therapeutics plc
£0.06-1.33%10
OXB.XLONOxford Biomedica plc
£4.89-4.68%26
ONT.XLONOxford Nanopore Technologies plc
£1.88-5.91%18
NFX.XLONNuformix Plc
£0.00+0.00%10
GNS.XLONGenus plc
£20.76-2.35%62

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing HEMO.XLON

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.